Kangmei Pharmaceutical Co., Ltd. (600518.SS)
CNY 2.58
(-0.39%)
CNY 2.58
(-0.39%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -317.52 Million | -749.96 Million | 214.2 Million | 1.03 Billion | 2.88 Billion | 305.61 Million |
| Net Income | 103.56 Million | -2.69 Billion | 7.91 Billion | -27.74 Billion | -4.65 Billion | 370.04 Million |
| Depreciation & Amortization | 346.17 Million | 365.68 Million | 603.22 Million | 627.76 Million | 695.13 Million | 500.17 Million |
| Deferred income taxes | -8.42 Million | 20.54 Million | 166.02 Million | 15.71 Million | 128.22 Million | -16.37 Million |
| Stock-based compensation | - | - | - | - | -98.04 Million | 56.38 Million |
| Change in working capital | -782.71 Million | 748.01 Million | -14.5 Billion | 2.75 Billion | 4.01 Billion | -2.75 Billion |
| Other non-cash items | 15.44 Million | 830.65 Million | 6.19 Billion | 25.39 Billion | 2.79 Billion | 2.19 Billion |
| Investing Cash Flow | -37.64 Million | -46.02 Million | -36.51 Million | 832.05 Million | -168.76 Million | -4.65 Billion |
| Investments in PPE | -99.74 Million | -48.11 Million | -171.62 Million | -301.72 Million | -473.2 Million | -4.59 Billion |
| Acquisitions | 9.85 Million | 1.54 Million | 57.71 Million | 5236.24 | 29.25 Million | -69.28 Million |
| Investment purchases | - | -1.54 Million | -10 Thousand | - | -6.95 Million | -1.5 Million |
| Sales/Maturities of investments | - | 547.61 Thousand | 36.46 Thousand | - | 320 Million | 12 Million |
| Other Investing Activities | 52.24 Million | 1.54 Million | 77.37 Million | 1.13 Billion | -37.85 Million | 1.51 Million |
| Financing Cash Flow | -120.84 Million | -116.86 Million | 1.76 Billion | -1.87 Billion | -4.04 Billion | 1.98 Billion |
| Debt repayment | -72.7 Million | -94.95 Million | -97.03 Million | -11.41 Billion | -12.7 Billion | -29.61 Billion |
| Dividends payments | - | -40.73 Thousand | -13.82 Million | -1.03 Billion | -344.37 Million | -3.01 Billion |
| Common Stock Repurchased | - | - | - | - | - | -2.62 Million |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -120.84 Million | -21.86 Million | 1.87 Billion | 10.57 Billion | 11.2 Billion | 34.62 Billion |
| Accounts receivables | 215.14 Million | -339.52 Million | -746.88 Million | 3.13 Billion | 956.59 Million | -2.22 Billion |
| Accounts payables | -896.41 Million | 1.32 Billion | -15.58 Billion | -2.29 Billion | 1.17 Billion | 1.32 Billion |
| Inventory | -93 Million | -253.62 Million | 1.66 Billion | 1.91 Billion | 1.75 Billion | -1.83 Billion |
| Other working capital | -8.42 Million | 20.54 Million | 166.02 Million | 15.03 Million | 128.22 Million | -916.85 Million |
| Cash at beginning of period | 1.43 Billion | 2.34 Billion | 398.7 Million | 411.83 Million | 1.74 Billion | 4.09 Billion |
| Cash at end of period | 955.88 Million | 1.43 Billion | 2.34 Billion | 398.7 Million | 411.83 Million | 1.74 Billion |
| Capital Expenditure | -99.74 Million | -48.11 Million | -171.62 Million | -301.72 Million | -473.2 Million | -4.59 Billion |
| Effect of forex changes on cash | 2821.42 | 2207.60 | -37.38 Thousand | -246.77 Thousand | 350.39 Thousand | 218.42 Thousand |
| Net cash flow / Change in cash | -476 Million | -912.84 Million | 1.94 Billion | -13.13 Million | -1.33 Billion | -2.35 Billion |
| Free Cash Flow | -417.26 Million | -798.07 Million | 42.57 Million | 729.66 Million | 2.4 Billion | -4.28 Billion |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -10.74 Million | 8.28 Million | 7.47 Million | 250.53 Million | 103.56 Million | -22.15 Million |
| Depreciation & Amortization | - | 90.07 Million | 90.07 Million | 92.22 Million | 346.17 Million | -170.19 Million |
| Deferred income taxes | - | - | - | - | -8.42 Million | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -377.26 Million | - | 122.13 Million | -782.71 Million | 51.59 Million |
| Other non-cash items | -20.08 Million | 95.48 Million | -340.02 Million | -529.09 Million | 15.44 Million | 77.61 Million |
| Investing Cash Flow | -2.1 Million | -105.68 Thousand | 28.21 Million | -32.14 Million | -37.64 Million | -8.9 Million |
| Investments in PPE | -10.63 Million | -12.16 Million | -14.41 Million | -51.62 Million | -99.74 Million | -9.26 Million |
| Acquisitions | 8.97 Million | 12.05 Million | 7.5 Million | 19.33 Million | 9.85 Million | 502.52 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 8.53 Million | 11.85 Million | 42.62 Million | 145.19 Thousand | 52.24 Million | -145.19 Thousand |
| Financing Cash Flow | -14.15 Million | -13.14 Million | -8.94 Million | -38.86 Million | -120.84 Million | -31.81 Million |
| Debt repayment | - | - | - | - | -72.7 Million | -47.44 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 710.62 Thousand | -710.62 Thousand | - | - | - | 12.41 Million |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -14.15 Million | 8.48 Million | -8.94 Million | -38.86 Million | -120.84 Million | 3.2 Million |
| Accounts receivables | - | -133.89 Million | - | 215.14 Million | 215.14 Million | 89.96 Million |
| Accounts payables | - | - | - | - | -896.41 Million | - |
| Inventory | - | -243.37 Million | - | -93 Million | -93 Million | -38.36 Million |
| Other working capital | - | - | - | - | -8.42 Million | - |
| Cash at beginning of period | 643.03 Million | 744.68 Million | 955.88 Million | 1.09 Billion | 1.43 Billion | 1.19 Billion |
| Cash at end of period | 595.94 Million | 794.96 Million | 642.59 Million | 955.88 Million | 955.88 Million | 1.09 Billion |
| Capital Expenditure | -10.63 Million | -12.16 Million | -14.41 Million | -51.62 Million | -99.74 Million | -9.26 Million |
| Effect of forex changes on cash | -593.70 | -519.49 | -1095.74 | -3022.71 | 2821.42 | 1646.25 |
| Net cash flow / Change in cash | -47.09 Million | 50.28 Million | -313.29 Million | -135.22 Million | -476 Million | -103.85 Million |
| Free Cash Flow | -41.47 Million | 1.53 Million | -346.97 Million | -115.83 Million | -417.26 Million | -72.39 Million |
TOKYOPLAST
NEXNF
SPACK
ABLV
FNINF
NGD